UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

Current Report

to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 30, 2003

NeoPharm, Inc.

(Exact name of registrant as specified in its charter)

Delaware		33-90516		51-0327886
(State or Other Jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

150 Field Drive, Suite 195, Lake Forest, IL 60045

(Address of principal executive offices) (Zip Code)

(847) 295-8678

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Item 7. Financial Statements and Exhibits

Exhibit Number		Description

99.1		Press Release dated July 1, 2003

Item 9. Regulation FD Disclosure

On July 1, 2003, the Company issued a press release, a copy of which is attached hereto as Exhibit 99.1, announcing the adoption of a Stockholder Rights Plan.

SIGNATURE PAGE

Pursuant to the requirements of The Securities and Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		NEOPHARM, INC.


Dated July 1, 2003	By:	/s/ LAWRENCE A. KENYON
			Chief Financial Officer
			(Principal Accounting Officer and
			Principal Financial Officer)